Skip to Main Content

Paper Details

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Neurol
160
2020
Author NameAffiliation
Yuko ShimizuTokyo Women's Medical University School of Medicine
Atsushi UmemuraClinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital
  • 1 - 2

Datasets

Release 1.2